A consortium of investors led a $200m Series A round in Treeline Biosciences.

A consortium of investors, including Access Industries, ARCH Venture Partners, OrbiMed, GV, KKR, T. Rowe Price Associates, Ajax Health/Zeus, Casdin Capital, Fidelity Management & Research Company, Aisling Capital, Rock Springs Capital, and Exor, led a $200m Series A round in Treeline Biosciences, a clinical-stage biopharma company. “We aspire to create the next great enduring biopharma company. “Our funding mandate has allowed us to recruit proven scientists, rigorously test assumptions, and curate a pipeline from parallel discovery efforts. BCL6 and KRAS are formidable targets that require difficult chemistry and novel assay development. We hope these programs deliver for patients and create momentum for our next set of clinical entries," Josh Bilenker, M.D., Treeline, Co-Founder and CEO.